Developing new drugs to treat skin injuries caused by arsenic exposure
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin Injury
This study is looking at how certain harmful chemicals from warfare can hurt the skin, and it's trying to find new treatments to help reduce pain and swelling for people who might be affected by these chemicals.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10923895 on NIH RePORTER |
What this research studies
This research focuses on understanding how arsenic-based chemicals, which have been used in warfare, cause severe skin injuries. By using animal models that mimic human skin reactions, the researchers aim to identify the biological mechanisms behind the damage caused by these toxic agents. The goal is to develop novel drugs that can effectively reduce inflammation, pain, and skin blistering resulting from arsenic exposure. Patients who may be affected by such exposures could benefit from the therapeutic strategies developed through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been exposed to arsenic compounds, whether through chemical warfare or accidental exposure.
Not a fit: Patients who have not been exposed to arsenic or similar toxic agents are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for skin injuries caused by arsenic exposure, improving recovery and quality of life for affected individuals.
How similar studies have performed: Previous research has shown promise in understanding the mechanisms of arsenic-induced skin damage, but this specific approach to drug development is relatively novel.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Athar, Mohammad — University of Alabama at Birmingham
- Study coordinator: Athar, Mohammad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.